Tandem Diabetes Care Announces Technology Access Program To Provide Customers With Purchase Pathway To The Tandem Mobi System For $199
Portfolio Pulse from Benzinga Newsdesk
Tandem Diabetes Care, Inc. (NASDAQ:TNDM) has announced a limited time offer for its Tandem Choice technology access program. This program allows new and renewing t:slim X2 Insulin Pump customers in the US to purchase the Tandem Mobi System for $199. The Tandem Mobi, recently cleared by the FDA, is expected to launch later this year with general availability in early 2024.
August 04, 2023 | 2:39 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Tandem Diabetes Care's new offer could potentially increase sales of the Tandem Mobi System, positively impacting the company's revenues.
The new offer from Tandem Diabetes Care provides a cost-effective pathway for customers to purchase the Tandem Mobi System. This could potentially lead to an increase in sales of the product, thereby positively impacting the company's revenues. The fact that the Tandem Mobi has been cleared by the FDA further strengthens the potential for increased sales.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100